Startups Directory

Biotechnology company producing cultivated meat.

Biotechnology company producing cultivated meat.

A new concept that makes the meat industry more sustainable, reducing resource use and providing a quality product.

€100 000

€150 000

At CYBERNA, we are building a technological platform to develop blood-based diagnostic solutions aimed at transforming oncology through ultra-early cancer detection. Unlike conventional approaches that detect tumors or their released markers (ctDNA, CTC), CYBERNA detects the earliest cellular environment changes that occur before tumors exist. By focusing on the epitranscriptome — an additional layer of information on RNA that dynamically reflects how cells adapt to their environment — our proprietary platform moves cancer detection upstream, making it possible to act before a tumor develops. Operating under a biotech-inspired model, we develop transferable diagnostic assets —patented biomarker signatures & chemical standards, validated know-how, and performance data — and license them to partners. For IVD companies, our technologies strengthen product pipelines and offer regulation-compliant solutions to expand or replace flagship products, while US CLIA labs unlock revenue expansion, faster market access, and strong competitive advantage. Our lead program focuses on colorectal cancer in high-risk populations. We are currently raising capital to bring this test to a licensing-ready stage. The investment will support a prospective 500-patient clinical study and the expansion of our development capabilities, generating high-value data, strengthening our IP portfolio, and positioning the company for strategic licensing opportunities.

At CYBERNA, we are building a technological platform to develop blood-based diagnostic solutions aimed at transforming oncology through ultra-early cancer detection. Unlike conventional approaches that detect tumors or their released markers (ctDNA, CTC), CYBERNA detects the earliest cellular environment changes that occur before tumors exist. By focusing on the epitranscriptome — an additional layer of information on RNA that dynamically reflects how cells adapt to their environment — our proprietary platform moves cancer detection upstream, making it possible to act before a tumor develops. Operating under a biotech-inspired model, we develop transferable diagnostic assets —patented biomarker signatures & chemical standards, validated know-how, and performance data — and license them to partners. For IVD companies, our technologies strengthen product pipelines and offer regulation-compliant solutions to expand or replace flagship products, while US CLIA labs unlock revenue expansion, faster market access, and strong competitive advantage. Our lead program focuses on colorectal cancer in high-risk populations. We are currently raising capital to bring this test to a licensing-ready stage. The investment will support a prospective 500-patient clinical study and the expansion of our development capabilities, generating high-value data, strengthening our IP portfolio, and positioning the company for strategic licensing opportunities.

Unlike conventional approaches that detect tumors or their released markers (ctDNA, CTC), CYBERNA detects the earliest cellular environment changes that occur before tumors exist

3-5M€

5M€

Nailfold capillaroscopy software with artificial intelligence

Nailfold capillaroscopy software with artificial intelligence

It will help in the early diagnosis of pathologies with microvascular affectation, and will improve the follow-up of these patients with objective and quantified metrics.

0

Not raising funds

Engineering consultancy with consistent focus on disruptive innovation across different sectors such as energy, mobility and healthcare

Engineering consultancy with consistent focus on disruptive innovation across different sectors such as energy, mobility and healthcare

Enhance training procedures of future healthcare professionals

500k €

N/A

Blesol Tech is a university spin-off from the University of Castilla-La Mancha (UCLM) specialising in the development and industrial scaling of high-performance metal and ceramic materials for Powder Injection Moulding (PIM) and sinter-based Additive Manufacturing. Founded in 2020, the company delivers injectable and 3D-printable feedstocks that enable the production of complex, high-performance components for demanding sectors such as aerospace, energy, biomedical, automotive and advanced electronics, with a strong focus on circular economy, material recycling and energy-efficient manufacturing.

Blesol Tech is a university spin-off from the University of Castilla-La Mancha (UCLM) specialising in the development and industrial scaling of high-performance metal and ceramic materials for Powder Injection Moulding (PIM) and sinter-based Additive Manufacturing. Founded in 2020, the company delivers injectable and 3D-printable feedstocks that enable the production of complex, high-performance components for demanding sectors such as aerospace, energy, biomedical, automotive and advanced electronics, with a strong focus on circular economy, material recycling and energy-efficient manufacturing.

By enabling tailored material design and bridging the gap between prototyping and cost-effective mass production, Blesol Tech accelerates the deployment of advanced, high-performance components in strategic sectors such as aerospace, energy, automotive and biomedical applications. Our technology reduces development time, lowers production costs, minimises raw material consumption and industrial waste, and decreases the environmental footprint of advanced manufacturing, supporting circular economy models, cleaner production processes and more resilient regional industrial value chains.

N/A

N/A

AidTec is a technology startup specializing in data-driven solutions for agriculture. We develop compact sensing systems and digital tools that monitor environmental and crop conditions in real time, enabling precision decision-making for growers. Our mission is to bring accessible, high-value technology to the field by combining electronics, IoT and data analytics to improve efficiency, sustainability and crop quality.

AidTec is a technology startup specializing in data-driven solutions for agriculture. We develop compact sensing systems and digital tools that monitor environmental and crop conditions in real time, enabling precision decision-making for growers. Our mission is to bring accessible, high-value technology to the field by combining electronics, IoT and data analytics to improve efficiency, sustainability and crop quality.

Our technology has a positive impact on society by making agriculture more sustainable, efficient and resilient. By providing growers with real-time data and predictive insights, we help reduce unnecessary chemical treatments, optimize water use and lower the environmental footprint of food production. This contributes directly to healthier ecosystems and more responsible resource management. Moreover, our tools democratize access to technology in rural areas, supporting small and medium growers, improving economic stability in agricultural regions, and fostering generational renewal in the sector. By transforming traditional farming into a data-driven activity, our technology empowers communities, strengthens local economies and promotes a more sustainable and climate-adapted agricultural future.

€100.000

€100000

ATENXIA is a deep-tech digital health platform powered by artificial intelligence that personalizes cognitive training to improve attention, executive functions, and literacy skills in children with ADHD and learning difficulties such as dyslexia. Developed in collaboration with leading academic research centers and based on scientifically validated methodologies, ATENXIA bridges cutting-edge neuroscience and real-world education and healthcare, enabling scalable, evidence-based early intervention.

ATENXIA is a deep-tech digital health platform powered by artificial intelligence that personalizes cognitive training to improve attention, executive functions, and literacy skills in children with ADHD and learning difficulties such as dyslexia. Developed in collaboration with leading academic research centers and based on scientifically validated methodologies, ATENXIA bridges cutting-edge neuroscience and real-world education and healthcare, enabling scalable, evidence-based early intervention.

ATENXIA generates a positive societal impact by enabling early, accessible, and evidence-based intervention for children with ADHD and learning difficulties such as dyslexia. By improving attention, executive functions, and literacy skills at early stages, the platform helps reduce school failure, dropout rates, and long-term mental health risks. ATENXIA also supports educators and healthcare professionals with objective data, contributing to more inclusive education systems, reduced inequality in access to care, and better long-term educational and social outcomes.

200.000€

200.000€

As a spin off of IMDEA Nutrition, we provide microbiome analysis for clinical and scientific purposes.

As a spin off of IMDEA Nutrition, we provide microbiome analysis for clinical and scientific purposes.

We expect to improve health by microbiome interventions

we are currently funded for 2026

€75,000

The company focuses on developing implantable devices to address musculoskeletal injuries. Currently available solutions have certain limitations, whether due to restricting patient movement, causing future injuries, or a combination of both. These new developments would minimize these problems, improving patients' daily lives and reducing future healthcare costs. Additionally, the company offers surgical planning services, surgical analysis, and the production of intraoperative instruments.

The company focuses on developing implantable devices to address musculoskeletal injuries. Currently available solutions have certain limitations, whether due to restricting patient movement, causing future injuries, or a combination of both. These new developments would minimize these problems, improving patients' daily lives and reducing future healthcare costs. Additionally, the company offers surgical planning services, surgical analysis, and the production of intraoperative instruments.

Improving the quality of life for patients, reducing future injuries, and saving healthcare costs arising from these injuries.

N/A

350.000 - 500.000€

MgShell is a spinoff from Politecnico di Milano developing an innovative magnesium-based drug delivery solution dedicated to transforming ophthalmic care by addressing a critical need in the treatment of age-related macular degeneration (AMD), a leading cause of blindness among individuals over 50 in developed countries. As the number of affected patients rises, therapeutic adherence remains low, with many failing to follow treatment regimens, leading to vision loss. The primary need expressed by both patients and clinicians is to reduce the frequency of injections and appointments while maintaining visual acuity outcomes. MgShell has developed an intraocular biodegradable drug delivery device that replicates the current treatment protocol without requiring surgery. By releasing preloaded doses of medication at preset intervals, the patented drug carrier, made of magnesium, substantially decreases the need for intravitreal injections, alleviating the burdens of existing clinical practices. This innovation significantly improves patient compliance, reduces healthcare costs, and offers business potential for pharmaceutical companies. MgShell’s solution stands out as the only device capable of replicating current therapeutic practices by autonomously releasing active ingredients at preset times, without the need for surgery or external device activation.

MgShell is a spinoff from Politecnico di Milano developing an innovative magnesium-based drug delivery solution dedicated to transforming ophthalmic care by addressing a critical need in the treatment of age-related macular degeneration (AMD), a leading cause of blindness among individuals over 50 in developed countries. As the number of affected patients rises, therapeutic adherence remains low, with many failing to follow treatment regimens, leading to vision loss. The primary need expressed by both patients and clinicians is to reduce the frequency of injections and appointments while maintaining visual acuity outcomes. MgShell has developed an intraocular biodegradable drug delivery device that replicates the current treatment protocol without requiring surgery. By releasing preloaded doses of medication at preset intervals, the patented drug carrier, made of magnesium, substantially decreases the need for intravitreal injections, alleviating the burdens of existing clinical practices. This innovation significantly improves patient compliance, reduces healthcare costs, and offers business potential for pharmaceutical companies. MgShell’s solution stands out as the only device capable of replicating current therapeutic practices by autonomously releasing active ingredients at preset times, without the need for surgery or external device activation.

The economic and social impact generated by MgShell is broad and measurable. Current management of age-related macular degeneration involves significant organizational complexity: each treatment requires an average of 4.5 hours per appointment and approximately 6.5 total hours including preparation, travel, and post-visit recovery. Moreover, 71% of patients require assistance from a family member or caregiver, and 53% of patients of working age must take leave from work to receive treatment. These figures highlight the strong economic and social burden of traditional treatment, affecting patients, caregivers, the healthcare system, and the broader economic fabric. MgShell intervenes concretely in this scenario by introducing a device that drastically reduces the number of required injections and allows controlled and continuous medication release over time. The result is an increase of at least 40% in therapeutic adherence: patients, no longer required to undergo frequent and invasive procedures, maintain therapy more consistently, avoiding interruptions that often compromise treatment effectiveness and vision preservation. For healthcare systems, MgShell represents a revolution in efficiency. The reduction in sessions and personnel involved leads to a 67% decrease in indirect and operational costs per patient, freeing up economic and human resources. This helps reduce the burden on healthcare facilities and makes it possible to allocate time and operational capacity to other patients, particularly those suffering from geographic atrophy, who will require increasingly intensive and complex care in the future. MgShell therefore contributes to a more balanced and efficient distribution of medical resources, optimizing the sustainability of the healthcare system as a whole. Social benefits are equally profound and widespread. The reduction in invasive procedures and frequent visits improves patients’ quality of life, decreasing stress, pain, and anxiety associated with treatment. Families and caregivers—who currently bear much of the assistance burden—experience real relief thanks to the reduced need for accompaniment and support. Greater adherence to therapy results in better vision preservation, increased personal autonomy, and reduced risk of isolation or loss of independence. From an environmental standpoint, the device introduces tangible and measurable benefits. The drastic reduction in treatment frequency results in a significant decrease in the use of syringes, plastics, and disposable materials used in intravitreal procedures, significantly reducing clinical waste generation. Furthermore, the use of magnesium—a fully biodegradable and biocompatible material—eliminates the need for device removal and does not leave harmful residues in the body or environment. Additionally, the reduced number of patient trips to hospitals lowers emissions associated with transportation. Thus, MgShell aligns with the sustainable medicine model, where technological innovation contributes not only to human health but also environmental preservation.

€ 3 Million

Up to € 5 Million

We accelerate innovation in the electronic manufacturing industry by enabling faster, more accurate simulations powered by AI and materials science

We accelerate innovation in the electronic manufacturing industry by enabling faster, more accurate simulations powered by AI and materials science

This technology will enable the development of more sustainable and environmentally friendly products, reducing environmental impact and contributing to a more sustainable society.

€300K

€600K

We are founding a RF technology startup idea focused on scalable sensing solutions based on radar, wireless communication, and RF energy transfer. Our long-term vision is to build an RF ecosystem where devices can sense, communicate, and operate with minimal maintenance, including battery-free operation enabled by wireless power transfer (WPT) and ultra-low-power electronics. Combining radar technology, RF hardware, embedded systems, and AI-driven signal processing, we will develop practical products such as radar-based sensing platforms, electronic warfare solutions and passive IoT sensors for applications in security, non-invasive healthcare monitoring, passive tracking, and smart infrastructure.

We are founding a RF technology startup idea focused on scalable sensing solutions based on radar, wireless communication, and RF energy transfer. Our long-term vision is to build an RF ecosystem where devices can sense, communicate, and operate with minimal maintenance, including battery-free operation enabled by wireless power transfer (WPT) and ultra-low-power electronics. Combining radar technology, RF hardware, embedded systems, and AI-driven signal processing, we will develop practical products such as radar-based sensing platforms, electronic warfare solutions and passive IoT sensors for applications in security, non-invasive healthcare monitoring, passive tracking, and smart infrastructure.

Improves public safety by enabling early detection of unauthorized drones in airports, critical infrastructures, and private properties; Democratizes access to advanced drone detection technology through a low-cost, low-power, and portable system suitable for civil authorities and private operators; Reduces operational disruptions and security risks by combining radar sensing with real-time AI-based decision-making; Supports safer integration of drones into society by providing reliable monitoring tools rather than reactive or invasive countermeasures.

N/A

N/A

Develop a contactless identification/authentication solution based on FMCW radar to recognize individuals through their gait signatures. The system integrates data acquisition, a complete signal-processing pipeline, structured feature extraction, and classification. Target applications include access control, security, and monitoring in environments where cameras are intrusive or less robust, while providing improved privacy.

Develop a contactless identification/authentication solution based on FMCW radar to recognize individuals through their gait signatures. The system integrates data acquisition, a complete signal-processing pipeline, structured feature extraction, and classification. Target applications include access control, security, and monitoring in environments where cameras are intrusive or less robust, while providing improved privacy.

This technology can improve societal safety and quality of life by enabling contactless, privacy-preserving sensing. In practice, it can support safer and more hygienic access control (no badges/PINs/touch-based biometrics) and can also contribute to health-oriented monitoring by detecting mobility patterns related to gait in a non-intrusive way. Because it does not rely on cameras, it can reduce privacy concerns in sensitive environments while remaining robust in low-light or occluding scenarios. This approach also encourages innovation in human-centric sensing, with potential to reduce operational costs and improve reliability in security and healthcare contexts.

N/A

N/A

The project aims to develop an oral GLP-1 therapy using circRNA technology. circRNA is naturally stable and resistant to degradation, making it ideal for sustained therapeutic applications. Our circRNA is engineered to encode GLP-1 and delivered through a drug delivery system that protects it during gastrointestinal transit and enables targeted release in the intestine. Once absorbed by enteroendocrine cells located in the intestinal epithelium, the circRNA enables continuous, regulated production of GLP-1, restoring the natural mechanism that controls blood glucose and appetite in healthy individuals. This endogenous, self-regulating approach treats both type 2 diabetes and obesity while eliminating the need for weekly injections and cold-chain storage, making it accessible to populations worldwide.

The project aims to develop an oral GLP-1 therapy using circRNA technology. circRNA is naturally stable and resistant to degradation, making it ideal for sustained therapeutic applications. Our circRNA is engineered to encode GLP-1 and delivered through a drug delivery system that protects it during gastrointestinal transit and enables targeted release in the intestine. Once absorbed by enteroendocrine cells located in the intestinal epithelium, the circRNA enables continuous, regulated production of GLP-1, restoring the natural mechanism that controls blood glucose and appetite in healthy individuals. This endogenous, self-regulating approach treats both type 2 diabetes and obesity while eliminating the need for weekly injections and cold-chain storage, making it accessible to populations worldwide.

Our technology will democratize diabetes treatment globally. By making it oral, affordable, and requiring minimal infrastructure, we enable access for the 853 million people projected to have diabetes by 2050. This improves health outcomes, reduces disease complications, and enables individuals to remain productive.

N/A

N/A

Human-based products for 3D cell culture and bioprinting designed to accelerate drug discovery while reducing animal testing.

Human-based products for 3D cell culture and bioprinting designed to accelerate drug discovery while reducing animal testing.

Metatissue’s technology has the potential to create a profound and multi-layered impact on society. By using human-derived tissues such as blood and placenta, we provide materials that are far more accurate and predictive than current animal-based options. This increased accuracy can accelerate drug development and help pharmaceutical companies avoid costly failures, ultimately saving billions in R&D and bringing effective treatments to patients much faster while allowing secondary effects to be better predicted and avoided. This improvement in efficiency naturally leads to broader societal benefits. Faster and more reliable development pipelines translate into earlier access to safer, more effective therapies, improving patient outcomes and strengthening healthcare systems. At the same time, because our materials are xeno-free and sustainable, they substantially reduce the need for animal testing and replace animal-derived products with ethical, human-relevant alternatives. In essence, our technology enables faster innovation, safer medicines, reduced costs, and a meaningful shift toward more ethical, human-relevant biomedical research, directly improving both people’s health and the future of science.

€1 Milllion

€1 M